- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Shirley Today
By the People, for the People
Creative Biolabs Expands Rodent Behavioral Profiling for CNS Drug Discovery
Upgraded platform offers integrated cognitive and motor assessments to accelerate preclinical development of neurological treatments.
Mar. 21, 2026 at 8:38am
Got story updates? Submit your updates here. ›
Creative Biolabs, a leading preclinical research services provider, has announced the expansion of its in vivo pharmacology capabilities with an upgraded rodent behavioral profiling platform. Designed specifically for central nervous system (CNS) research, the enhanced platform offers highly standardized evaluations of both cognitive and motor functions to help reduce the translational gap in the development of therapeutics for neurodegenerative diseases.
Why it matters
The clinical attrition rate for CNS therapeutics remains historically high, frequently due to the lack of predictive preclinical models that accurately reflect complex human neuropathology. Creative Biolabs' upgraded platform aims to address this challenge by providing a more holistic efficacy profile for pipeline candidates, integrating cognitive and neuromuscular assessments to better capture the nuanced, multifaceted progression of neurodegeneration.
The details
The enhanced platform offers a robust suite of comprehensive rodent behavioral tests for cognition, utilizing industry-standard paradigms such as the Morris Water Maze, Novel Object Recognition, and Y-Maze to quantitatively evaluate spatial learning, working memory, and recognition. Simultaneously, the company provides advanced assessments of rodent motor function, incorporating automated Rotarod tests, grip strength measurements, and open-field locomotor tracking to detect subtle therapeutic improvements or neurotoxicities in motor coordination, balance, and muscle endurance.
- Creative Biolabs announced the expansion of its in vivo pharmacology capabilities on March 21, 2026.
The players
Creative Biolabs
A leading preclinical research services provider that has expanded its in vivo pharmacology capabilities with an upgraded rodent behavioral profiling platform.
Director of In Vivo Pharmacology at Creative Biolabs
Stated that the predictive validity of any CNS animal model relies heavily on the sensitivity and reproducibility of the behavioral assays applied, and that integrating these dual-assessment platforms has successfully supported multiple IND applications for novel neuroprotective agents.
What they’re saying
“The predictive validity of any CNS animal model relies heavily on the sensitivity and reproducibility of the behavioral assays applied. Based on recent partner milestones, integrating these dual-assessment platforms has successfully supported multiple IND applications for novel neuroprotective agents.”
— Director of In Vivo Pharmacology
The takeaway
Creative Biolabs' upgraded rodent behavioral profiling platform, which offers integrated cognitive and motor assessments, aims to help reduce the translational gap in the development of therapeutics for neurodegenerative diseases by providing a more holistic efficacy profile for pipeline candidates.
